The Belgrade, Mont.-based company, which was formed after Bacterin paid $86 million for spinal implant maker X-Spine Systems, said president Carl O’Connell will step in as interim CEO while the company’s board “contemplates the permanent CEO,” according to a press release.
“We are thankful for Dan’s significant contributions to the Company during his tenure as chief executive. Under Dan’s leadership, the company has made significant progress toward our strategic goals,” chairman Kent Swanson said in prepared remarks. “We are fortunate to have Carl O’Connell agree to serve as interim CEO. Carl is an accomplished senior executive with a demonstrated history of leading marketing and sales organizations and deep healthcare and medical device experience. We look forward to working with Carl as we embark on the next phase of the company’s growth.”
Sequana Medical said founder, president and CEO Noel Johnson, died suddenly last month.
Johnson founded Sequana in 2006 based on his idea for a fully implantable, battery-powered pump to treat refractory ascites, or chronic fluid build-up in the abdomen, the company said in a Dec. 22 press release.
“The board and all employees are greatly saddened by Noel’s passing, and indebted to Noel for his boundless energy and dedication, and significant contribution to Sequana Medical. Throughout his time with Sequana Medical, Noel was dedicated to improving the quality of life of patients living with this debilitating disease. The availability of the Alfapump system for refractory ascites patients in Europe is due in great part of Noel’s hard work and commitment. The board’s thoughts are with Noel’s family at this difficult time,” the company said.
Johnson had already begun to process of handing over the reins to Ian Crosbie, who was named CFO in July 2016. Read more